SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-012176
Filing Date
2024-04-01
Accepted
2024-04-01 09:00:29
Documents
16
Period of Report
2024-03-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48130
2 ex10-1.htm EX-10.1 31830
3 ex10-2.htm EX-10.2 29871
  Complete submission text file 0001493152-24-012176.txt   343265

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cldi-20240328.xsd EX-101.SCH 3893
5 XBRL DEFINITION FILE cldi-20240328_def.xml EX-101.DEF 26803
6 XBRL LABEL FILE cldi-20240328_lab.xml EX-101.LAB 37082
7 XBRL PRESENTATION FILE cldi-20240328_pre.xml EX-101.PRE 25427
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6130
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

IRS No.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 24805807
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)